Olmesartan Medoxomilo + Hidroclorotiazida Tolife (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxil combined with Hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis.

• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Resistant hypertension: provides additional blood‑pressure control when monotherapy is insufficient.
• Hypertension with fluid retention: reduces plasma volume and vascular resistance, improving overall control.

• Olmesartan medoxil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water. The combined effect reduces peripheral vascular resistance and plasma volume, leading to sustained blood‑pressure reduction.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first doses.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Increased urination: due to the diuretic component, may be noticeable initially.
• Electrolyte imbalance: mild reductions in potassium or sodium levels.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or airway requiring immediate medical attention.
• Severe dehydration: excessive fluid loss leading to hypotension.
• Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease.
• Hyperkalemia: elevated potassium levels, potentially dangerous if untreated.
• Severe hypotension: marked drop in blood pressure causing fainting or shock.

Before initiating therapy, consider the following precautions:

• Monitor blood pressure: ensure adequate control and avoid excessive lowering.
• Assess renal function: check serum creatinine and eGFR periodically.
• Check electrolytes: especially potassium and sodium levels during treatment.
• Use caution in hepatic impairment: dose adjustments may be needed.
• Avoid in severe dehydration: rehydrate before starting the combination.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil + Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren: combined use can cause excessive potassium elevation and renal impairment.
• Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia.
• Lithium: increased lithium levels may lead to toxicity.
• ACE inhibitors: additive effect on potassium and renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may cause additive blood‑pressure lowering.
• Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.
• CYP450 inhibitors (e.g., ketoconazole): may increase olmesartan plasma concentrations.